Following the restructuring, the spin-off company will be engaged in manufacturing, research and development and sales of pharmaceutical and medicinal cannabis products. These activities are currently undertaken by iX Biopharma’s wholly-owned subsidiaries iX Syrinx, Arrow Property Trust, iX Biopharma, iX Biopharma Europe and iXB.
iX Biopharma is exploring a spin-off of its pharmaceutical business, including medical cannabis, by way of a listing on the main board of The Stock Exchange of Hong Kong (HKEX).
In a filing to the Singapore Exchange (SGX) on July 12, the company disclosed it intends to restructure its pharmaceutical business to be held by Ligo Pharma, a wholly-owned subsidiary incorporated in the Cayman Islands.
